Multiplex Assay Kit for Myostatin (MSTN) ,etc. by FLIA (Flow Luminescence Immunoassay) 
GDF8; Growth Differentiation Factor 8
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 498.00 US$ 517.00 US$ 546.00 US$ 584.00 US$ 623.00 US$ 680.00 US$ 766.00 US$ 958.00
- Quantity
Overview
Properties
- Product No.LMB653Po
- Organism SpeciesSus scrofa; Porcine (Pig) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryCytokineMetabolic pathwayBone metabolism
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Myostatin (MSTN) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Myostatin (MSTN) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 87-94 | 91 |
| EDTA plasma(n=5) | 80-99 | 85 |
| heparin plasma(n=5) | 92-99 | 96 |
| sodium citrate plasma(n=5) | 93-103 | 97 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Myostatin (MSTN) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Myostatin (MSTN) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Myostatin (MSTN) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 85-95% | 78-103% | 95-105% | 97-104% |
| EDTA plasma(n=5) | 93-101% | 87-104% | 95-105% | 96-103% |
| heparin plasma(n=5) | 87-96% | 90-104% | 83-92% | 79-102% |
| sodium citrate plasma(n=5) | 85-97% | 83-94% | 97-104% | 82-103% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:MSTN) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- Anti-Myostatin Reduces Bone Mineral Loss in Ovariectomized RatsSapub:Source
- Short-term, high-fat diet accelerates disuse atrophy and protein degradation in a muscle-specific manner in micePubMed: 26539241
- Tumor inoculation site affects the development of cancer cachexia and muscle wastingPubMed: 26016447
- Induction of transient tenogenic phenotype of high density cultured human dermal fibroblastsPubMed: 25748814
- Higher Plasma Myostatin Levels in Cor Pulmonale Secondary to Chronic Obstructive Pulmonary DiseasePubmed:26998756
- The Effect of Vibration Treatments Combined with Teriparatide or Strontium Ranelate on Bone Healing and Muscle in Ovariectomized RatsPubmed:27272029
- Irisin and Myostatin Levels in Patients with Graves' Disease.pubmed:27986127
- Effect of Strontium Ranelate on the Muscle and Vertebrae of Ovariectomized Ratspubmed:29242963
- Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis.pubmed:28740214
- Fermented corn-soybean meal elevated IGF1 levels in grower-finisher pigsPubmed: 30203098
- Predictive value of serum myostatin for the severity and clinical outcome of heart failurePubmed: 31056368
- Resistance training‐induced muscle hypertrophy is mediated by TGF‐β1‐Smad signaling pathway in male Wistar ratsPubmed: 31960436
- Myostatin and muscle atrophy during chronic kidney diseasePubmed: 32974666
- Gender-Specific Behaviour in Obesity Stages I-II: Imbalance of Aminothiol Status and Adipomyokine Profile in Subjects with Different Insulin Resistance …34868459